This article was originally published in SRA
Australian guidance outlines penalties for breach of regulations
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
A pharmaceutical industry consortium gives the thumbs up for using blockchain technology to track and trace products through the supply chain to meet DSCSA mandate, yet says new standards are necessary.
Lilly is positioning the ramucirumab/erlotinib combination as a first-line alternative for EGFR-positive non-small cell lung cancer that preserves AstraZeneca’s Tagrisso for second-line use; advisory committee members vote 6-5 for expanded indication but express skepticism about adoption.